Apeiron Signs Regional License Agreements with Medison Pharma (Israel) and Gen Ilac ve Saglik Ürünleri (Turkey) for the Commercialization of its Neuroblastoma Therapy

Apeiron today announced the signing of two transactions as part of the worldwide commercialization of APN311, an antibody-based immunotherapy in development for the treatment of children suffering from high-risk neuroblastoma.

Press release